***** Accentia Biopharmaceuticals reports that data in SinuNase Phase 3 trial predicts that virtually 100% of Chronic Sinusitis cases due to fungal-induced inflammation (ABPI) 2.49 : Co announced evidence that most, if not all cases of chronic sinusitis (CS), are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the Company's ongoing pivotal Phase 3 clinicaltrial for its lead pharmaceutical product, SinuNase(TM), an intranasal formulation of the antifungal amphotericin B 0.01% suspension. SinuTest(TM), the diagnostic used to measure eMBP in the nasal mucin, is a patented technology developed at the Mayo Foundation for Medical Education and Research. The technology is exclusively licensed to IMMCO Diagnostics, which hasan exclusive commercialization agreement with Accentia Biopharmaceuticals. TheCompany believes that SinuTest will be a useful adjunct for identification ofpatients who are suspected of having CS and who may be candidates for treatmentwith SinuNase, assuming FDA approval.
Caspermick
"TOUGH TIMES NEVER LAST BUT TOUGH PEOPLE DO."
God Bless America
In Gambling,,,Playing Card Games. Ya Never Know What The Next Hand Will Look Like.
Ten Bagger Potential Stock
